The markers support non-invasive early detection, and may help reliably distinguish between healthy individuals and those with cervical cancer
A study from Sun Yat-sen University in Guangzhou shows: Combination of the biomarkers Apo10 and TKTL1 reliably detects early-stage breast cancer – and is able to distinguish between malignant and benign tumors.
A study conducted by Sun Yat-sen University in Guangzhou provides initial evidence that the biomarkers Apo10 and TKTL1 can help detect lung cancer at an early stage and distinguish it from benign pulmonary nodules.
In an interview with the newspaper Die Welt, HanseMerkur CEO Eberhard Sautter says of the PanTum Detect®: "The test contained in our 'Krebs-Scan' has therefore closed a gap."
The Shield test from US company Guardant Health is the first blood test for the early detection of cancer to receive important FDA approval in the USA. Shield has been approved as a primary screening option for colorectal cancer.
Vision Zero board member: "Blood tests will revolutionize cancer medicine!" (translated); PanTum Detect® patient report: Zyagnum blood test gave decisive indication of tumor.
DUP magazine reports: The gene TKTL1 controls cell division. It could also revolutionize the early detection and treatment of cancer.
Following pandemic-related declines, there is once again a positive trend regarding participation in cancer screening examinations.
At World Cancer Day 2023, the early detection program Krebs-Scan was presented at the HanseMerkur symposium "Earlier Helps Better".